Indicators
Indicators
Value
Direction
MACD(12,26,9)
-0.026
Sell
RSI(14)
26.593
Sell
STOCH(KDJ)(9,3,3)
9.900
Oversold
ATR(14)
0.129
High Vlolatility
CCI(14)
-83.926
Neutral
Williams %R
95.041
Oversold
TRIX(12,20)
-1.892
Sell
StochRSI(14)
29.319
Sell
Ensysce Biosciences Inc
ENSC1.110USD
-0.010-0.89%
Close 12/24, 13:00（ET）Quotes delayed by 15 min
3.53MMarket Cap
LossP/E TTM
TradingKey Stock Score
Overall Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Peer Comparison
TradingKey Stock Score of Ensysce Biosciences Inc
Currency: USD Updated: 2025-12-24Key Insights
Ensysce Biosciences Inc's fundamentals are relatively healthy, and its growth potential is significant.Its valuation is considered fairly valued, ranking 241/404 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as , with the highest price target at 26.23.In the medium term, the stock price is expected to trend down.Despite a very weak stock market performance over the past month, the company shows strong fundamentals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Ensysce Biosciences Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Analyst Rating
Based on
0
analysts
--
Current Rating
26.225
Target Price
+1539.06%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Ensysce Biosciences Inc Highlights
StrengthsRisks
Ensysce Biosciences, Inc. is a clinical-stage pharmaceutical company. The Company develops solutions for severe pain relief while reducing the potential for opioid misuse, abuse, and overdose. Its pipeline includes two new drug platforms: an abuse-resistant opioid prodrug technology, the Trypsin Activated Abuse Protection (TAAP) platform, and an over-dose protection opioid prodrug technology, the Multi-Pill Abuse Resistant (MPAR) platform. Its lead product, PF614, is a TAAP extended-release oxycodone and a potential analgesic to treat severe pain. Its second product, PF614-MPAR, is to treat severe pain with the added benefit of oral overdose protection, is a combination product of the TAAP prodrug PF614 with a trypsin inhibitor. Additionally, nafamostat, which is an ingredient in its overdose protection combination products, is also being developed for the intended purpose of treating infection and pulmonary lung diseases.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 106.47% year-on-year.
Growing
The company is in a growing phase, with the latest annual income totaling USD 5.21M.
Overvalued
The company’s latest PE is -0.18, at a high 3-year percentile range.
Held by The Vanguard
Star Investor The Vanguard holds 36.71K shares of this stock.
Financial Health
Currency: USD Updated: 2025-12-24The current financial score of Ensysce Biosciences Inc is 6.00, ranking 312/404 in the Biotechnology & Medical Research industry. Its financial status is stable, and its operating efficiency is low. Its latest quarterly revenue reached 493.10K, representing a year-over-year decrease of 85.58%, while its net profit experienced a year-over-year decrease of 663.51%.
Score
Financials
7.70
Key Metrics
Cash and cash equivalents
Total assets
Total liabilities
Free cash flow
Relevant data have not been disclosed by the company yet.
Quality of Earnings
7.00
Operational Efficiency
3.72
Growth Potential
4.53
Shareholder Returns
7.07
Ensysce Biosciences Inc's Company Valuation
Currency: USD Updated: 2025-12-24The current valuation score of Ensysce Biosciences Inc is 7.03, ranking 191/404 in the Biotechnology & Medical Research industry. Its current P/E ratio is -0.18, which is -22.84% below the recent high of -0.14 and -8430.44% above the recent low of -14.94.
Score
Valuation Dimensions
P/E
P/B
P/S
P/CF
Industry Ranking 241/404
Relevant data have not been disclosed by the company yet.
Earnings Forecast
Currency: USD Updated: 2025-12-24No earnings forecast score is currently available for Ensysce Biosciences Inc. The Biotechnology & Medical Research industry's average is 8.02. The average price target for Ensysce Biosciences Inc is 26.23, with a high of 34.00 and a low of 18.45.
Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
No Data
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Relevant data have not been disclosed by the company yet.
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Price Momentum
Currency: USD Updated: 2025-12-24The current price momentum score of Ensysce Biosciences Inc is 2.81, ranking 386/404 in the Biotechnology & Medical Research industry. Currently, the stock price is trading between the resistance level at 1.61 and the support level at 0.84, making it suitable for range-bound swing trading.
Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Indicators
The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.
This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.
Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.
Moving Average
Indicators
Value
Direction
MA5
1.142
Sell
MA10
1.212
Sell
MA20
1.416
Sell
MA50
1.814
Sell
MA100
2.000
Sell
MA200
2.223
Sell
Institutional Confidence
Currency: USD Updated: 2025-12-24The current institutional shareholding score of Ensysce Biosciences Inc is 3.00, ranking 197/404 in the Biotechnology & Medical Research industry. The latest institutional shareholding proportion is 16.57%, representing a quarter-over-quarter decrease of 1.84%. The largest institutional shareholder is The Vanguard, holding a total of 36.71K shares, representing 1.04% of shares outstanding, with 1.00% increase in holdings.
Score
Institutional Shareholding
Relevant data have not been disclosed by the company yet.
Shareholder Activity
Name
Shares Held
Chg %
Perceptive Advisors LLC
Adage Capital Management, L.P.
Geode Capital Management, L.L.C.
1
2
Risk Assessment
Currency: USD Updated: 2025-12-24The current risk assessment score of Ensysce Biosciences Inc is 3.19, ranking 167/404 in the Biotechnology & Medical Research industry. The company's beta value is 1.16. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets.
Score
Beta vs S&P 500 index
1.16
VaR
+12.02%
240-Day Maximum Drawdown
+86.59%
240-Day Volatility
+135.44%
Return
Best Daily Return
60 days
+11.27%
120 days
+11.27%
5 years
+161.77%
Worst Daily Return
60 days
-12.28%
120 days
-12.28%
5 years
-53.36%
Sharpe Ratio
60 days
-3.67
120 days
-2.12
5 years
-0.61
Risk Assessment
Maximum Drawdown
240 days
+86.59%
3 years
+99.14%
5 years
--
Return-to-Drawdown Ratio
240 days
-0.98
3 years
-0.33
5 years
--
Skewness
240 days
+7.17
3 years
+7.36
5 years
+5.81
Volatility
Realised Volatility
240 days
+135.44%
5 years
--
Standardised True Range
240 days
+23.24%
5 years
--
Downside Risk-Adjusted Return
120 days
-262.84%
240 days
-262.84%
Maximum Daily Upside Volatility
60 days
+49.03%
Maximum Daily Downside Volatility
60 days
+66.28%
Liquidity
Average Turnover Rate
60 days
+24.49%
120 days
+70.88%
5 years
--
Turnover Deviation
20 days
-98.69%
60 days
-95.94%
120 days
-88.26%
Peer Comparison
Biotechnology & Medical Research
Ensysce Biosciences Inc
ENSC
3.74 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Amicus Therapeutics Inc
FOLD
8.82 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
IQVIA Holdings Inc
IQV
8.67 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Dynavax Technologies Corp
DVAX
8.56 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
BioCryst Pharmaceuticals Inc
BCRX
8.50 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Krystal Biotech Inc
KRYS
8.46 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
View more
FAQs
How does TradingKey generate the Stock Score of Ensysce Biosciences Inc?
The TradingKey Stock Score provides a comprehensive assessment of Ensysce Biosciences Inc based on 34 indicators derived from over 100 underlying data points. These indicators are categorised into six key dimensions: financial health, company profile, earnings forecasts, price momentum, institutional confidence, and risk assessment, collectively providing investors with a thorough analysis of Ensysce Biosciences Inc’s performance and outlook.
How do we generate the financial health score of Ensysce Biosciences Inc?
To generate the financial health score of Ensysce Biosciences Inc, we analyse various key financial indicators across several core dimensions, including financial fundamentals, earnings quality, operational efficiency, growth potential, and shareholder returns. By integrating these comprehensive data, the financial health score not only reflects Ensysce Biosciences Inc's overall stability, operational efficiency, and growth potential but also captures the investment returns delivered to shareholders. This score aims to support rational decision-making for investors and other stakeholders. A higher score indicates a better financial health of Ensysce Biosciences Inc.
How do we generate the company valuation score of Ensysce Biosciences Inc?
To generate the company valuation score of Ensysce Biosciences Inc, we use several key financial ratios, including P/E, P/B, P/S, and P/CF. These metrics compare Ensysce Biosciences Inc’s market value to its earnings, assets, sales, and cash flow, serving as core indicators for assessing company value. By analysing these ratios in an all-round manner, the valuation score reflects not only the market’s current perception of Ensysce Biosciences Inc’s value but also its future profitability and growth potential, thereby supporting more informed investment decisions. A higher score indicates a fairer valuation of Ensysce Biosciences Inc.
How do we generate the earnings forecast score of Ensysce Biosciences Inc?
To calculate the earnings forecast score of Ensysce Biosciences Inc, we consider various key indicators such as analyst ratings, financial forecasts, support and resistance levels, and peer comparisons:Current ratings and price targets directly reflect analysts’ expectations, while the upside space indicates their views on the stock’s growth potential.Financial metrics like earnings per share (EPS), revenue, net income, and earnings before interest and taxes (EBIT) are core measures for assessing profitability.By analysing the high, median, and low ranges of the target price, we can identify price trends and determine key support and resistance levels.Comparing these indicators against peers provides context for the stock’s performance and helps
anchor more realistic expectations.These factors together form a comprehensive earnings forecast score that accurately reflects the stock’s expected financial performance and growth potential. A higher score suggests that analysts have a more optimistic outlook on Ensysce Biosciences Inc’s future.
How do we generate the price momentum score of Ensysce Biosciences Inc?
When generating the price momentum score for Ensysce Biosciences Inc, we examine momentum indicators including support and resistance levels as well as volume metrics.Support levels represent price points where buying interest is strong enough to prevent further declines, while resistance levels indicate prices where selling pressure may hinder upward movement. By analysing typical price volume alongside total volume, we assess overall market activity and liquidity. These indicators help identify price trends and potential shifts, enabling more accurate predictions of future earnings.This comprehensive approach can reflect market sentiment and enable rational forecasts of Ensysce Biosciences Inc’s prices. A higher score indicates a more stable short-term price trend for Ensysce Biosciences Inc.
How do we generate the institutional confidence score of Ensysce Biosciences Inc?
To generate the institutional confidence score of Ensysce Biosciences Inc, we analyse both the proportion of shares held by institutions and the number of shares they own. A higher institutional ownership percentage indicates strong confidence of professional investors, which is generally a positive signal about Ensysce Biosciences Inc’s potential. By examining the number of shares held, we gain deeper insight into institutions’ commitment and attitude toward the stock, as institutional investors typically conduct thorough analysis before making investment decisions. Understanding institutional confidence helps us refine earnings forecasts and provides a more reliable perspective on the company’s future performance and market stability. A higher score indicates greater institutional endorsement of Ensysce Biosciences Inc.
How do we generate the risk management score of Ensysce Biosciences Inc?
To assess the risk management score of Ensysce Biosciences Inc, we examine multiple key indicators related to returns, risk, volatility, and liquidity.The highest and lowest daily returns reflect the potential size of gains and losses, while the Sharpe ratio measures risk-adjusted return performance. On the risk side, we analyse maximum drawdown and the return-to-drawdown ratio to identify extreme loss scenarios. Skewness helps assess the distribution of returns and whether performance may be biased. Volatility indicators—such as realised volatility and standardised true range—reveal price fluctuations. Downside risk-adjusted returns provide insight into potential losses and gains. Lastly, liquidity metrics like average turnover rate and turnover deviation indicate how actively the stock is traded.These indicators together provide a multi-dimensional understanding of Ensysce Biosciences Inc’s risk-return profile, serving as core factors of the risk management score. A higher score indicates lower risk on the side of Ensysce Biosciences Inc.
